Skip to content
lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Decoy Therapeutics, Inc
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
August 3, 2026
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
July 27, 2026
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
May 26, 2026
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
April 9, 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
April 6, 2026
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 2, 2026
Decoy Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recently Announced Global Access Commitment Agreement
February 10, 2026